PRIA Logo™
119-s-4751119th CongressWALLET

End Tuberculosis Now Act of 2026

Sponsored By: Senator Young, Todd [R-IN]

Introduced

Summary

A comprehensive, goal-driven global TB program to dramatically reduce tuberculosis worldwide. This bill would declare TB a continuing global public health emergency and would direct U.S. foreign assistance to expand diagnosis, treatment, prevention, and research while setting ambitious 2027–2030 targets.

Show full summary
  • Families and patients: Expands diagnosis and treatment for adults and children, including latent TB and drug-resistant TB, and aims to provide TB preventive treatment to 30 million people.
  • Health systems and high-burden countries: Prioritizes active case finding, integration of molecular diagnostics, infection control in hospitals and prisons, sustainable procurement of quality medicines, and support for MDR-TB and XDR-TB and HIV co-infection care.
  • Researchers and oversight: Funds research and public-private partnerships for vaccines, rapid diagnostics, and shorter treatments, requires annual reporting to Congress, and mandates a Government Accountability Office review of program performance.

Personalized for You

How does this bill affect your finances?

Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Free to download

Bill Overview

Analyzed Economic Effects

3 provisions identified: 2 benefits, 1 costs, 0 mixed.

More U.S. support to fight TB

If enacted, the President would be authorized to give bilateral and other foreign aid to prevent, diagnose, treat, and eliminate tuberculosis. Grants would have rules to reduce patient costs, fund health worker training, support lab networks and molecular diagnostics, and buy quality tests and medicines. The bill would emphasize cost‑effective procurement, including annual U.S. support for the Global Drug Facility, and require patient- and community-led outreach. This authorization would take effect on enactment and would end on January 1, 2033 unless reauthorized.

Stronger tuberculosis reporting and research

If enacted, the President would send Congress an annual report on U.S. TB assistance with country- and site-level results, spending, and patient support figures. The Secretary of State would also deliver an annual tuberculosis research and development report starting within one year of enactment and continuing through December 31, 2032. The Government Accountability Office would evaluate U.S. bilateral TB programs and report to Congress within four years of enactment. These steps would increase oversight, track progress toward the bill's targets, and highlight research gaps.

U.S. TB program ends January 2033

If enacted, the statutory changes in this bill would stop having effect beginning January 1, 2033. That end date would terminate the authorization for bilateral TB assistance, reporting, and related mandates unless Congress reauthorizes them. This would limit how long the new U.S. authorities and requirements would last.

Sponsors & CoSponsors

Sponsor

Young, Todd [R-IN]

IN • R

Cosponsors

  • Sen. Shaheen, Jeanne [D-NH]

    NH • D

    Sponsored 6/11/2026

Roll Call Votes

No roll call votes available for this bill.

View on Congress.gov
Back to Legislation